Status:
RECRUITING
Verapamil for Neuroprotection in Stroke
Lead Sponsor:
Global Neurosciences Institute
Conditions:
Ischemic Stroke
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this research study is to test an experimental procedure called intra-arterial delivery of verapamil in patients diagnosed with acute ischemic stroke. This study investigates the safety...
Eligibility Criteria
Inclusion
- Written informed consent
- 18 years of age and over
- Acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia
- Candidate for mechanical thrombectomy procedure
- Onset of symptoms less than 8 hours
- Measurable neurologic deficit (NIHSS ≥4)
- Willingness to follow up with rehabilitation therapy
- Anticipated life expectancy of at least 3 months
Exclusion
- Pregnancy or suspected pregnancy (pregnancy test will be done on women of child-bearing potential)
- Hepatic and/or renal insufficiency (LFT's\>3× upper limit of normal; CrCl \< 30ml/min)
- Thrombocytopenia (platelet count \<75,000/mm3)
- History of intolerance to verapamil
- Previous functional disability (modified Rankin \> 1)
- Severe stroke (NIHSS\>22)
- Stuporous or comatose
- Unlikely to be available for 90 day follow-up
Key Trial Info
Start Date :
April 20 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03347786
Start Date
April 20 2017
End Date
December 1 2026
Last Update
January 17 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
AtlantiCare Regional Medical Center
Atlantic City, New Jersey, United States, 08401
2
St Mary Medical Center
Langhorne, Pennsylvania, United States, 19047
3
Crozer Chester Medical Center
Upland, Pennsylvania, United States, 19013